Get the Stockscreener App
7.00
5.15%
-0.38
Pre-market:
6.86
-0.14
-2.00%
Neuraxis Inc stock is traded at $7.00, with a volume of 117.92K.
It is down -5.15% in the last 24 hours and down -10.94% over the past month.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
See More
Previous Close:
$7.38
Open:
$7.39
24h Volume:
117.92K
Relative Volume:
0.63
Market Cap:
$86.69M
Revenue:
$3.57M
Net Income/Loss:
$-7.80M
P/E Ratio:
-7.2143
EPS:
-0.9703
Net Cash Flow:
$-6.56M
1W Performance:
-3.45%
1M Performance:
-10.94%
6M Performance:
+162.17%
1Y Performance:
+131.02%
1-Day Range:
$6.95
$7.49
1-Week Range:
$6.95
$7.60
52-Week Range:
$2.1963
$9.33
Neuraxis Inc Stock (NRXS) Company Profile
Name
Neuraxis Inc
Sector
Industry
Phone
(812) 689-0791
Address
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
7.00 | 91.40M | 3.57M | -7.80M | -6.56M | -0.9703 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neuraxis Inc Stock (NRXS) Latest News
Neuraxis Inc. (NRXS) Holds Near Support After Marginal DeclineMA Cross Alert - Newser
Neuraxis Inc. (NRXS) Q1 2026 Earnings: Narrower Loss Beats Estimates, but Stock Slips on Pre‑Revenue Concerns - Newser
NeurAxis Earnings Call Highlights Growth and Hurdles - TipRanks
Minot Light Capital Fund Drops 2.7 Percent Amid Sector Rotation - HarianBasis.co
NeurAxis (NRXS) Climbs on Reimbursement and Guideline Momentum - Insider Monkey
Neuraxis (NRXS) Stock Analysis: -5.84% Loss — Key Levels 2026-05-18Stock Idea Hub - Newser
NeurAxis slides 21%, raises $5M via stock - MSN
The surprise hidden in Neuraxis NRXS last earnings report Q4 2025 Earnings Beat EstimatesCrowd Verified Signals - Newser
NeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/Y - Yahoo Finance
NeurAxis revenues up 80% to USD 1.6M in Q1 2026 - Medical Buyer
Craig-Hallum Sticks to Its Buy Rating for NeurAxis, Inc. (NRXS) - The Globe and Mail
TradingKey - TradingKey
NeurAxis signals burn rate of $1M or less for rest of 2026 while targeting ~ $15M revenue for cash flow breakeven - MSN
Neuraxis Inc (NRXS) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Coverage Challenges - Investing.com Canada
Earnings call transcript: Neuraxis Q1 2026 sees record revenue growth - Investing.com
Neuraxis Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
NRXS: Q1 2026 revenue up 80% year-over-year, with margin and adoption gains in covered markets - TradingView
NeurAxis, Inc. Reports 80% Revenue Growth in Q1 2026 Driven by CPT Code Assignment and Expanded Product Adoption - Quiver Quantitative
Neuraxis, INC 1Q 2026: Revenue $1.61M, EPS $(0.18) — 10-Q Summary - TradingView
NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth - GlobeNewswire
NeurAxis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
The surprise hidden in Neuraxis (NRXS) last earnings report | Q4 2025: Earnings Beat EstimatesCommunity Risk Signals - newser.com
Neuraxis | ARS: Annual Report to Security Holders - Moomoo
NeurAxis (NRXS) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
What the smart money sees in Neuraxis (NRXS) that retail does not (Near Lows) 2026-05-08Open Stock Picks - newser.com
Number of shareholders of Neuraxis, Inc. – AMEX:NRXS - TradingView
NRXS Neuraxis Q4 loss narrows more than expected, but shares dip 0.11% despite EPS beat.CFO Commentary - newser.com
The critical factors shaping Neuraxis (NRXS) future (Technical Weakness) 2026-05-08Retail Trader Ideas - newser.com
This Small-Cap Healthcare Stock Is Up 300% in a Year and Is Quickly Gaining a Following - inkl
NeurAxis will post first-quarter results before market open May 12 - Stock Titan
NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026 - GlobeNewswire
The Zacks Analyst Blog Highlights Alphabet, Walmart, Micron Technology and NeurAxis - Yahoo Finance
Top stock reports for Alphabet, Walmart & Micron - MSN
Bigger Capital, Michael Bigger report NRXS holdings (NRXS) and warrant limits - Stock Titan
Neuraxis | SCHEDULE 13G/A: Others - Moomoo
Neuraxis (NRXS) director Gil reports stock awards from Series B dividend - Stock Titan
Neuraxis | 4: Statement of changes in beneficial ownership of securities-Director Aharon Gil - Moomoo
NeurAxis (NRXS) price target increased by 29.41% to 11.22 - MSN
NRXS Ownership | NEURAXIS INC (NYSEARCA:NRXS) - ChartMill
Neuraxis (NRXS) asks investors to expand 2022 stock plan and approve ESPP - Stock Titan
Neuraxis | DEF 14A: Definitive information statements - Moomoo
NeurAxis (NRXS) price target increased by 21.43% to 8.67 - MSN
NeurAxis (NASDAQ:NRXS) Trading Up 5.5%Here's What Happened - MarketBeat
NRXS Should I Buy - Intellectia AI
NeurAxis Expands At-The-Market Equity Offering Capacity - The Globe and Mail
Neuraxis increases at-the-market offering capacity to $11.5 million on NYSE American - Investing.com India
Neuraxis increases ATM capacity to $11.5M after $6.27M program sales - TradingView
Neuraxis (NRXS) boosts at-the-market share sale capacity to $11.5M - Stock Titan
Neuraxis, Inc. Files Form 8-K Current Report with SEC – Company Details, Address, and Trading Information (April 21, 2026) 345726 - Minichart
NeurAxis Inc (NYSEARCA:NRXS) Shows Strong Technical and Fundamental Momentum - ChartMill
1.25 million more people gain access to NeurAxis' IBS pain device - Stock Titan
Neuraxis Inc Stock (NRXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Cap:
|
Volume (24h):